|
|
Publication
|
| Title of Article |
Combined OPCML and AXL Expression as a Prognostic Marker and OPCML
Enhances AXL Inhibitor in Cholangiocarcinoma |
| Date of Acceptance |
10 March 2022 |
| Journal |
| Title of Journal |
In Vivo |
| Standard |
ISI |
| Institute of Journal |
International Institute of Anticancer Research |
| ISBN/ISSN |
|
| Volume |
|
| Issue |
|
| Month |
|
| Year of Publication |
2022 |
| Page |
|
| Abstract |
Background/Aim: Cholangiocarcinoma (CCA) is a type of liver cancer
originating from bile duct epithelium which has an unfavorable prognosis. Therefore,
novel prognostic markers and effective therapeutic regimens are required. Opioidbinding
protein/cell adhesion molecule-like (OPCML) is a tumor-suppressor protein
that suppresses CCA cell proliferation via AXL receptor tyrosine kinase/signal
transducer and activator of transcription 3 (AXL/STAT3) inactivation. However, this
association in clinical samples remains unknown. We aimed to determine OPCML and
AXL expression and investigate their association with clinicopathological features in
patients with CCA. In addition, we also addressed whether OPCML enhanced the
sensitivity of CCA cells to AXL inhibitor R428 in vitro. Materials and Methods: The
expression of OPCML and AXL was determined by immunohistochemistry in 90 CCA
tissue samples. The study of CCA cell line sensitivity to R428 was performed by cell
viability assay. Results: The expression of OPCML was significantly lower while AXL
expression was substantially higher in CCA than in adjacent normal tissue (p<0.001).
Furthermore, high AXL expression was significantly associated with lymph node
metastasis (p=0.035). Interestingly, patients with combined low OPCML/high AXL
expression had significantly shorter overall survival (p=0.007). OPCML enhanced the
effect of AXL inhibitor R428 in AXL-expressing CCA cell lines. Conclusion: Combined
expression of OPCML and AXL shows potential value as a prognostic marker and
OPCML as an agent enhancing the effect of R428 may contribute to better prognosis
for patients with CCA. |
| Keyword |
OPCML, AXL, prognostic marker, AXL inhibitor R428, enhancing agent |
| Author |
|
| Reviewing Status |
ไม่มีผู้ประเมินอิสระ |
| Status |
ได้รับการตอบรับให้ตีพิมพ์ |
| Level of Publication |
นานาชาติ |
| citation |
false |
| Part of thesis |
true |
| Attach file |
|
| Citation |
0
|
|
|
|
|
|
|
|
|
Journal Publication
ไทย